Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised,Double-blind,Placebo-controlled,Multi National,Phase III Trial to Assess the Efficacy and Safety of 300 IR Sublingual Immunotherapy Administered as Allergen-based Tablets Once Daily to Adolescents and Children Above the Age of 5 Years, Suffering From House Dust Mite Allergic Rhinitis

NCT01199133 is registered in ClinicalTrials.gov with Stallergenes Greer as lead sponsor.

NCT NCT01199133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01199133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised,Double-blind,Placebo-controlled,Multi National,Phase III Trial to Assess the Efficacy and Safety of 300 IR Sublingual Immunotherapy Administered as Allergen-based Tablets Once Daily to Adolescents and Children Above the Age of 5 Years, Suffering From House Dust Mite Allergic Rhinitis
Lead sponsor
Stallergenes Greer
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2009
Completion date
September 30, 2011
Enrollment
471 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis due to dust mite